A Prophylaxis Order Nobody Re-Examined Since Intubation
A single patient on a prophylactic drug order that has run four days without anyone asking whether it still needs to be there. The disagreement is really about what a ventilated patient's risk profile has to include before continuing therapy is worth choosing all over again.
D.C., a 47-year-old man who runs a two-truck landscaping crew, is four days into a mechanical ventilation course following emergency surgery for a bowel obstruction — stable, weaning slowly, no coagulopathy, no shock, no history of GI bleeding or ulcer disease. Pantoprazole prophylaxis was started reflexively at intubation, the way it is for nearly every ventilated ICU patient at this hospital, and has simply continued unexamined through four days of otherwise careful daily rounding on everything else in his chart.
The evidence behind routine stress-ulcer prophylaxis is more contested than the reflexive ordering pattern suggests. SUP-ICU, Krag and colleagues' 2018 randomized trial, found pantoprazole no better than placebo on 90-day mortality in a broad at-risk ICU population, reopening a question that had been treated as settled for years. REVISE, Cook and colleagues' more targeted 2024 trial of 4,821 invasively ventilated patients, did find PPI prophylaxis meaningfully reduced clinically important GI bleeding — 1.0% against 3.5% on placebo — without a corresponding increase in ventilator-associated pneumonia or mortality — a genuinely reassuring result for the population that matters most, since ventilated patients are exactly where stress-related mucosal bleeding risk concentrates.
What the REVISE result doesn't settle is whether every ventilated patient benefits equally, or whether the benefit concentrates in patients who also carry additional risk factors — coagulopathy, shock, high-dose steroids, prior GI bleeding — that D.C. doesn't have. His actual bleeding risk, judged purely on ventilation status without those additional factors, sits close to the lower end of what REVISE's own population represented, and the theoretical (though REVISE-unconfirmed) concern that acid suppression alters gastric flora and modestly raises pneumonia risk hasn't fully left the conversation just because this trial didn't detect it. His enteral feeding, already established and tolerated by hospital day two, is itself a factor some clinicians weight in this exact decision — feeding provides its own mucosal-protective effect independent of acid suppression, a mechanism distinct from anything either drug offers and one more reason his particular risk profile sits toward the lower end of who genuinely needs continued prophylaxis.
An order four days old and never revisited
REVISE is the trial that actually matches his situation — mechanically ventilated patients specifically, not the broader mixed-ICU population SUP-ICU looked at — and it found a real reduction in clinically important GI bleeding with PPI prophylaxis, without a corresponding rise in pneumonia or mortality.
He's still ventilated, still four days out from major surgery. I'd continue pantoprazole through the remainder of his course rather than stop it on the strength of an older, less targeted trial.
REVISE is a real and relevant trial, and I'm not arguing it's wrong about the population it enrolled.
What I'd flag is that his own risk profile sits closer to the lower end of even that trial's population — no coagulopathy, no shock, no steroids, no prior bleeding history, and he's expected to extubate within the next couple of days. SUP-ICU's null mortality result and the still-unresolved theoretical pneumonia-risk signal haven't been fully retired just because REVISE didn't detect a ventilator-associated pneumonia difference in its own, narrower, ventilated-only population — and continuing a prophylaxis order past the point it's actively needed isn't a neutral default, it's its own decision.
I take the point that this order has run four days without anyone actually re-examining whether it's still earning its place, which is a fair criticism regardless of which way we land today.
Given he's expected to extubate within 48 to 72 hours and has no additional risk factors, I'd agree to stop prophylaxis now rather than carry it through an ICU stay that's already ending — with a clear note to restart if his course changes and additional risk factors appear.
Pantoprazole discontinued given his low additional-risk profile and expected extubation within 48 to 72 hours, with explicit restart criteria documented in his chart rather than left to whoever happens to be rounding if his course changes.
Agreed by both, though the disagreement's real value was in surfacing that the original order had simply never been re-examined — both physicians treated that as worth fixing as a rounding habit, independent of which way this particular patient's decision landed.